Posts By :

areisli

Lysogene Receives MHRA and Research Ethics Committee Approvals to Initiate the Gene Therapy Clinical Trial in the UK with LYS-GM101 for the Treatment of GM1 Gangliosidosis

Lysogene Receives MHRA and Research Ethics Committee Approvals to Initiate the Gene Therapy Clinical Trial in the UK with LYS-GM101 for the Treatment of GM1 Gangliosidosis 150 150 Lysogene

LYS-GM101 is Lysogene’s second CNS gene therapy program to enter clinicTrial enrollment expected to begin…

Lysogene Reports First Half 2020 Financial Results and Provides Operational Update

Lysogene Reports First Half 2020 Financial Results and Provides Operational Update 150 150 Lysogene

Cash position of €23.8m as of 30 June 2020 strengthened by a €7.7m capital increase ledby OrbiMed and Sarepta, extending cash runway to Q4 2021

Lysogene COVID-19 update

Get In Touch

Don’t hesitate to contact us if you need more help.

    Back to top